Skip to main content

Table 2 Univariate and multivariate Cox regression analyses associated with the risk of overall survival

From: Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child–Pugh grade B patients with locally advanced hepatocellular carcinoma

Variable

Univariate analysis

Multivariate analysis

HR

95%CI

p value

HR

95%CI

p value

Sex, male versus female

1.22

0.44–3.40

0.701

   

Age (years)

0.98

0.95–1.01

0.242

   

Bodyweight (kg)

1.00

0.98–1.03

0.883

   

Radiographic liver cirrhosis

1.37

0.80–2.34

0.252

   

Hepatitis etiology

      

Hepatitis B virus

0.70

0.33–1.49

0.358

   

Hepatitis C virus

1.81

0.56–5.84

0.322

   

Other

1.16

0.49–2.72

0.733

   

ECOG PS

0.87

0.46–1.65

0.667

   

0

      

1

      

2

      

Total bilirubin (μmol/L)

1.00

0.99–1.01

0.935

   

Albumin (g/L)

0.98

0.90–1.06

0.575

   

PT (sec)

1.00

0.84–1.17

0.954

   

Child–Pugh score

1.10

0.67–1.79

0.707

   

7

      

8

      

9

      

ALBI score

1.20

0.56–2.58

0.641

   

ALBI Grade, 2 versus 3

1.46

0.76–2.79

0.252

   

AST (U/L)

1.00

1.00–1.00

0.623

   

ALT (U/L)

1.00

1.00–1.00

0.923

   

ALP (U/L)

1.00

1.00–1.00

0.441

   

WBC (10^12/L)

1.00

0.92–1.08

0.986

   

HGB (g /L)

1.00

0.99–1.01

0.769

   

PLT (10^9/L)

1.00

1.00–1.00

0.238

   

ANC (10^9/L)

0.97

0.92–1.03

0.360

   

ALC (10^9/L)

0.86

0.50–1.49

0.588

   

Alpha fetoprotein (ng/ml), < 400 versus ≥ 400

1.57

0.92–2.69

0.101

   

Max tumor size (cm)

1.03

0.99–1.09

0.170

   

Tumor number, ≥ 3 versus < 3

1.49

0.87–2.55

0.148

   

Macrovascular invasion, yes versus no

1.65

0.90–3.00

0.104

   

Extrahepatic metastasis, yes versus no

0.98

0.57–1.68

0.936

   

BCLC stage

1.28

0.79–2.07

0.312

   

A

      

B

      

C

      

Dose per fraction

0.98

0.72–1.33

0.875

   

GTV (cc/ml)

1.00

1.00–1.00

0.372

   

EQD28 (Gy)

1.00

0.98–1.03

0.653

   

NLV (cc/ml)

1.00

1.00–1.00

0.573

   

Dmean (Gy)

1.04

0.99–1.09

0.143

   

Prior treatment

      

TACE

1.71

0.88–3.32

0.116

   

RFA

0.33

0.08–1.37

0.128

   

Surgical resection

0.54

0.30–0.97

0.039

0.60

0.33–1.08

0.088

Systemic therapy

0.65

0.34–1.21

0.211

   

ncRILD

3.32

1.81–6.08

 < 0.0001

3.08

1.67–5.66

 < 0.001

  1. ALBI, albumin–bilirubin; ALC, absolute lymphocyte count; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; Dmean, mean dose to the normal liver; ECOG PS, Eastern Cooperative Oncology Group-performance status; EQD2, equivalent dose in 2‑Gy fractions; GTV, gross tumor volume; HGB, hemoglobin; NLV, normal liver volume; OR, odds ratio; PLT, platelets; PT, prothrombin time; RFA, radiofrequency ablation; RT, radiotherapy; TACE, transcatheter chemoembolization; WBC, white blood cells; 8, using LQ model, α/β = 8 Gy
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us